Back to Authors

Atzler, Dorothee

0000-0002-6551-1544

Mayo Clinic

Institute for Cardiovascular Prevention (C.A.B., M.L., V.T., F.M.F., K.N., Y.W., V.B., I.A-K., Y.F.S.M., M.K., K.R., C.W., D.S., E.L., D.A.), Ludwig Maximilians Universität, Munich, Germany.

Citations 3

Ezh2 Shapes T Cell Plasticity to Drive Atherosclerosis
Bonfiglio, Cecilia Assunta , Lacy, Michael , Triantafyllidou, Vasiliki, Farina, Floriana Maria , Janjic, Aleksandar , Nitz, Katrin , Wu, Yuting , Marques, Yonara Freire Soares, Kumkum, Mahadia, Röß, Katja, Venkatasubramani, Anuroop Venkateswaran , Weber, Christian , Santovito, Donato , Joppich, Markus , Kumkum, Mahadia , Venkatasubramani, Anuroop Venkateswaran , Maegdefessel, Lars , de Winther, Menno P J , Weber, Christian , Santovito, Donato , Lutgens, Esther , Atzler, Dorothee , Bonfiglio, Cecilia A , Janjic, Aleksandar , Nitz, Katrin , Bazioti, Venetia , Avcilar-Kücükgöze, Irem , Röß, Katja, Imhof, Axel , Enard, Wolfgang , Winther, Menno P.J. de , Lutgens, Esther , Atzler, Dorothee

Circulation | February 7, 2025 | Volume: 151 | Issue: 19 | Pages: 1391-1408

10.1161/circulationaha.124.072384 Get It

BACKGROUND: The activation and polarization of T cells play a crucial role in atherosclerosis and dictate athero-inflammation. The epigenetic enzyme EZH2 (enhancer of zeste homolog 2) mediates the H3K27me3 (trimethylation of histone H3 lysine 27) and is pivotal in controlling T cell responses. METHODS: To detail the role of T cell EZH2 in atherosclerosis, we used human carotid endarterectomy specimens to reveal plaque expression and geography of EZH2. Atherosclerosis-prone Apoe (apolipoprotein E)–deficient mice with CD (cluster of differentiation) 4 + or CD8 + T cell–specific Ezh2 deletion (Ezh2 cd4 -knockout [KO], Ezh2 cd8 -KO) were analyzed to unravel the role of T cell Ezh2 in atherosclerosis and T cell–associated immune status. RESULTS: EZH2 expression is elevated in advanced human atherosclerotic plaques and primarily expressed in the T cell nucleus, suggesting the importance of canonical EZH2 function in atherosclerosis. Ezh2 cd4 -KO, but not Ezh2 cd8 -KO, mice showed reduced atherosclerosis with fewer advanced plaques, which contained less collagen and macrophages, indicating that Ezh2 in CD4 + T cells drives atherosclerosis. In-depth analysis of CD4 + T cells of Ezh2 cd4 -KO mice revealed that absence of Ezh2 results in a type 2 immune response with increased Il-4 (interleukin 4) gene and protein expression in the aorta and lymphoid organs. In vitro, Ezh2 -deficient T cells polarized macrophages toward an anti-inflammatory phenotype. Single-cell RNA-sequencing of splenic T cells revealed that Ezh2 deficiency reduced naive, Ccl5 + (C-C motif chemokine ligand 5) and regulatory T cell populations and increased the frequencies of memory T cells and invariant natural killer T (iNKT) cells. Flow cytometric analysis identified a shift toward Th2 (type 2 T helper) effector CD4 + T cells in Ezh2 cd4 -KO mice and confirmed a profound increase in splenic iNKT cells with increased expression of Plzf (promyelocytic leukemia zinc finger), which is the characteristic marker of the iNKT2 subset. Likewise, Zbtb16 ([zinc finger and BTB domain containing 16], the Plzf-encoding gene) transcripts were elevated in the aorta of Ezh2 cd4 -KO mice, suggesting an accumulation of iNKT2 cells in the plaque. H3K27me3–chromatin immunoprecipitation followed by quantitative polymerase chain reaction showed that T cell–Ezh2 regulates the transcription of the Il-4 and Zbtb16 genes. CONCLUSIONS: Our study uncovers the importance of T cell EZH2 in human and mouse atherosclerosis. Inhibition of Ezh2 in CD4 + T cells drives type 2 immune responses, resulting in an accumulation of iNKT2 and Th2 cells, memory T cells and anti-inflammatory macrophages that limit the progression of atherosclerosis.
The Amino Acid Homoarginine Inhibits Atherogenesis by Modulating T-Cell Function
Nitz, Katrin , Bianchini, Mariaelvy , Wichapong, Kanin , Avcilar-Kücükgöze, Irem , Bonfiglio, Cecilia Assunta , Migheli, Roberta , Wu, Yuting , Bürger, C., Li, Yuanfang , Forné, Ignasi , Mohanta, Sarajo K. , Duchêne, Johan , Heemskerk, Johan W. M. , Huveneers, Stephan , Lygate, Craig A. , Santovito, Donato , Zimmer, Ralf , Weber, Christian , Atzler, Dorothee , Nitz, Katrin , Wichapong, Kanin , Bonfiglio, Cecilia A , Migheli, Roberta , Li, Yuanfang , Forné, Ignasi , Ammar, Constantin , Janjic, Aleksandar , Heemskerk, Johan W M , Schwedhelm, Edzard , Huveneers, Stephan , Lygate, Craig A , Santovito, Donato , Zimmer, Ralf , Weber, Christian , Atzler, Dorothee , Nitz, Katrin , Nitz, Katrin , Lacy, Michael , Janjic, Aleksandar , Megens, Remco T. A. , Imhof, Axel , Lutgens, Esther

Circulation Research | September 14, 2022 | Volume: 131 | Issue: 8 | Pages: 701-712

10.1161/circresaha.122.321094 Get It

Background: Amino acid metabolism is crucial for inflammatory processes during atherogenesis. The endogenous amino acid homoarginine is a robust biomarker for cardiovascular outcome and mortality with high levels being protective. However, the underlying mechanisms remain elusive. We investigated the effect of homoarginine supplementation on atherosclerotic plaque development with a particular focus on inflammation. Methods: Female ApoE-deficient mice were supplemented with homoarginine (14 mg/L) in drinking water starting 2 weeks before and continuing throughout a 6-week period of Western-type diet feeding. Control mice received normal drinking water. Immunohistochemistry and flow cytometry were used for plaque- and immunological phenotyping. T cells were characterized using mass spectrometry–based proteomics, by functional in vitro approaches, for example, proliferation and migration/chemotaxis assays as well as by super-resolution microscopy. Results: Homoarginine supplementation led to a 2-fold increase in circulating homoarginine concentrations. Homoarginine-treated mice exhibited reduced atherosclerosis in the aortic root and brachiocephalic trunk. A substantial decrease in CD3 + T cells in the atherosclerotic lesions suggested a T-cell–related effect of homoarginine supplementation, which was mainly attributed to CD4 + T cells. Macrophages, dendritic cells, and B cells were not affected. CD4 + T-cell proteomics and subsequent pathway analysis together with in vitro studies demonstrated that homoarginine profoundly modulated the spatial organization of the T-cell actin cytoskeleton and increased filopodia formation via inhibition of Myh9 (myosin heavy chain 9). Further mechanistic studies revealed an inhibition of T-cell proliferation as well as a striking impairment of the migratory capacities of T cells in response to relevant chemokines by homoarginine, all of which likely contribute to its atheroprotective effects. Conclusions: Our study unravels a novel mechanism by which the amino acid homoarginine reduces atherosclerosis, establishing that homoarginine modulates the T-cell cytoskeleton and thereby mitigates T-cell functions important during atherogenesis. These findings provide a molecular explanation for the beneficial effects of homoarginine in atherosclerotic cardiovascular disease.
Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages’ transition into a pro-inflammatory state
Bosmans, Laura A. , Tiel, Claudia M. van , Aarts, Suzanne A. B. M. , Willemsen, Lisa , Baardman, Jeroen , Os, Bram W. van , Toom, Myrthe den, Beckers, Linda, Ahern, David , Levels, J.H.M. , Moerland, Perry D. , Verberk, Sanne G. S. , Winther, Menno M P J de, Weber, Christian , Atzler, Dorothee , Monaco, Claudia , Shami, Annelie , Winther, Menno P.J. de , den Bossche, Jan van , Weber, Christian , Monaco, Claudia , Shami, Annelie , Atzler, Dorothee , de Winther, Menno P J , van Os, Bram W , Jongejan, Aldo , Gerdes, Norbert , Lutgens, Esther

Cardiovascular Research | May 19, 2022 | Volume: 119 | Issue: 5 | Pages: 1146-1160

10.1093/cvr/cvac084 Get It

Abstract Aims CD40 and its ligand, CD40L, play a critical role in driving atherosclerotic plaque development. Disrupted CD40-signalling reduces experimental atherosclerosis and induces a favourable stable plaque phenotype. We recently showed that small molecule-based inhibition of CD40-tumour necrosis factor receptor associated factor-6 interactions attenuates atherosclerosis in hyperlipidaemic mice via macrophage-driven mechanisms. The present study aims to detail the function of myeloid CD40 in atherosclerosis using myeloid-specific CD40-deficient mice. Method and Results Cd40flox/flox and LysM-cre Cd40flox/flox mice on an Apoe−/− background were generated (CD40wt and CD40mac−/−, respectively). Atherosclerotic lesion size, as well as plaque macrophage content, was reduced in CD40mac−/− compared to CD40wt mice, and their plaques displayed a reduction in necrotic core size. Transcriptomics analysis of the CD40mac−/− atherosclerotic aorta revealed downregulated pathways of immune pathways and inflammatory responses. Loss of CD40 in macrophages changed the representation of aortic macrophage subsets. Mass cytometry analysis revealed a higher content of a subset of alternative or resident-like CD206+CD209b− macrophages in the atherosclerotic aorta of CD40mac−/− compared to CD40wt mice. RNA-sequencing of bone marrow-derived macrophages of CD40mac−/− mice demonstrated upregulation of genes associated with alternatively activated macrophages (including Folr2, Thbs1, Sdc1, and Tns1). Conclusions We here show that absence of CD40 signalling in myeloid cells reduces atherosclerosis and limits systemic inflammation by preventing a shift in macrophage polarization towards pro-inflammatory states. Our study confirms the merit of macrophage-targeted inhibition of CD40 as a valuable therapeutic strategy to combat atherosclerosis.